3 days popular7 days popular1 month popular3 months popular

Can low-dose interferon prevent relapse of hepatitis C virus infection?

(HCV) infection can lead to serious diseases such as cirrhosis and cancer of the liver, so and prevention of are important treatment goals. Low-dose oral interferon may reduce the risk of HCV in patients with mild according to a study published in Journal of Interferon & Cytokine Research, a peer-reviewed publication from , , publishers. The article is available free on the Journal of Interferon & Cytokine Research website.

In “A Double-Blind Randomized Controlled Study to Evaluate the Efficacy of Low-Dose Oral Interferon-Alpha in Preventing Hepatitis C Relapse,” Chuan-Mo Lee and coauthors from several universities and hospitals in Taiwan present the results of a clinical trial comparing the effects of 24 weeks of treatment with two doses of oral interferon-alpha or placebo in patients who achieved viral clearance after successful HCV therapy.

“This is a highly significant study relevant to the optimal use of IFN for HCV treatment,” says Co-Editor-in-Chief Ganes C. Sen, PhD, Chairman, Department of Molecular Genetics, Cleveland Clinic Foundation, Ohio.

Source

Mary Ann Liebert, Inc./Genetic Engineering News